



Express Mail No. EV654850885US
Sheet 1 of 2

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	709181-999261	10/647,072
	APPLICANT	
	Kroczek	
	FILING DATE	GROUP
	August 22, 2003	1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JO	A01	US-2002/0164697	11/2002	Coyle et al.			
	A02	US-2002/0156242	10/2002	Tamatani et al.			
	A03	US-2002/0151685	10/2002	Tamatani et al.			
	A04	US-2002/0115831	08/2002	Tamatani et al.			
	A05	09/509,283	08/11/2000	Kroczek (pending claims)			
	A06	09/823,307	04/02/2001	Kroczek (pending claims)			
JO	A07	09/972,524	10/04/2001	Kroczek (pending claims)			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
JO	B01	WO 00/46240 A	08/2000	WIPO					
	B02	WO 99/15553	04/01/99	PCT					
	B03	WO 98/38216	09/03/98	PCT					
	B04	EP 984 023	02/27/98	EU					
	B05	WO 90/04180	04/19/90	PCT					
	B06	WO 89/10398	11/02/89	PCT					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Barbey et al., 1990, "DEL cell line: a "malignant histiocytosis" CD30+ t(5;6)(q35;p21) cell line." Int J Cancer. 45(3):546-53
C02	Buonfiglio et al., 1999, "Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas", Eur. J. Immunol. 30:3463-3467
C03	Buonfiglio et al., 2000, "The T cell activation molecule H4 and the CD28-like molecule ICOS are identical", Eur. J. Immunol. 30:3463-3467
C04	Chambers and Allison, 1997, "Co-stimulation in T cell responses." Curr Opin Immunol. 9(3):396-404. Review
C05	Chirgwin et al., 1979, "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease." Biochemistry. 18(24):5294-9
C06	CRL 8001 ATCC Cell Lines and Hybridomas, page 393, 8 th edition, 1994 American Type Culture Collection catalog
C07	Dianzani et al., 1999, "Characterization of human H4, a novel surface molecule selectively expressed by activated T cells and mature thymocytes", FASEB Journal, 13(5):712-39
C08	Fischer et al., 1988, "A-K1-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene." Blood. 72(1):234-40
C09	Freeman et al., 1993, "Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation." Science. 262(5135):909-11
C10	Gonzalo et al., Nature Immunol. July 2001; 2(7):597-604
C11	Greenfield et al., 1998, "CD28/B7 costimulation: a review", Crit. Rev. Immunol. 18:389-418
C12	Goettrup et al., 1996, "A third interferon-gamma-induced subunit exchange in the 20S proteasome" Eur J Immunol. 26(4):863-9

Thia Desperksi

10/26/2006

	C13	Hara et al., 1985, "Human T cell activation, II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J Exp Med. 161(6):1513-24
10	C14	Keane-Myers et al., J. Immunol. January 15, 1998; 160:1036-1043
	C15	Kirk et al., 1997, "CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 94(16):8789-94
	C16	Kohler and Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity." Nature 256(5517):495-7
	C17	Kroczek RA., 1993, "Southern and northern analysis." J Chromatogr. 618(1-2):133-45.
	C18	Lanier et al., 1995, "CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL." J Immunol. 154(1):97-105
	C19	Lenschow et al., 1996, "CD28/B7 system of T cell costimulation", Annu. Rev. Immunol. 14:233-258
	C20	Linsley et al., 1992, "Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes." J Exp Med. 176(6):1595-604
e21	C21	Lucas et al., 1995, "Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response." J Immunol. 154(11):5757-68
	C22	Lucia et al., 2000, "Expression of the Novel T Cell Activation Molecule-hpH4 in HIV-Infected Patients: Correlation with Disease Status", Aids Research and Human Retroviruses, 16(6):549-557
10	C23	Mathur et al., Am. J. Respir. Cell Mol. Biol. 1999; 21:498-509
	C24	Nishioka et al., 1994, "The role of CD40-CD40 ligand interaction in human T cell-B cell collaboration." J Immunol. 153(3):1027-36
10	C25	Ozkaynak et al., Nature Immunol. July 2001; 2(7):591-596
	C26	Redoglia et al. 1996, "Characterization of H4: a mouse T lymphocyte activation molecule functionally associated with the CD3/T cell receptor", Eur. J. Immunol. 26:2781-2789
	C27	Regenmortel, METHODS: A companion to Methods in Enzymology 1996; 9:465-472
	C28	Riley et al., 1997, "Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation." J Immunol. 158(11):5545-53
	C29	Schneider et al., 1982, "A one-step purification of membrane proteins using a high efficiency immunomatrix. J Biol Chem. 257(18):10766-9
	C30	Shahinian et al., 1993, "Differential T cell costimulatory requirements in CD28-deficient mice." Science. 261(5121):609-12
	C31	Tamatani and Tezuka, Human Cell Surface Protein, Genseq Database Accession Number W75956
	C32	Tamatani and Tezuka, Human Cell Surface Protein, Genseq Database Accession Number V53199
	C33	Vogeli and Kaytes, 1987, "Amplification, storage, and replication of libraries." Methods Enzymol. 152:407-15
	C34	Wallace and Miyada, 1987, "Oligonucleotide probes for the screening of recombinant DNA libraries." Methods Enzymol. 152:432-42
	C35	Westermeier, 1997, "A Guide to Methods and Applications of DNA and Protein Separations." Electrophoresis in Practice, VCH Verlagsgesellschaft, Weinheim
10	C36	Willis-Karp M., Immunopharmacol. 2000; 48:263-268
	C37	Wozney, 1990, "Using purified protein to clone its gene." Methods Enzymol. 182:738-51

EXAMINER

Fiona Auspenski

DATE CONSIDERED

10/26/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.